Literature DB >> 17080728

Ultrastructural characteristics of tau filaments in tauopathies: immuno-electron microscopic demonstration of tau filaments in tauopathies.

Kunimasa Arima1.   

Abstract

The microtubule-associated protein tau aggregates into filaments in the form of neurofibrillary tangles, neuropil threads and argyrophilic grains in neurons, in the form of variable astrocytic tangles in astrocytes and in the form of coiled bodies and argyrophilic threads in oligodendrocytes. These tau filaments may be classified into two types, straight filaments or tubules with 9-18 nm diameters and "twisted ribbons" composed of two parallel aligned components. In the same disease, the fine structure of tau filaments in glial cells roughly resembles that in neurons. In sporadic tauopathies, individual tau filaments show characteristic sizes, shapes and arrangements, and therefore contribute to neuropathologic differential diagnosis. In frontotemporal dementias caused by tau gene mutations, variable filamentous profiles were observed in association with mutation sites and insoluble tau isoforms, including straight filaments or tubules, paired helical filament-like filaments, and twisted ribbons. Pre-embedding immunoelectron microscopic studies were carried out using anti-3-repeat tau and anti-4-repeat tau specific antibodies, RD3 and RD4. Straight tubules in neuronal and astrocytic Pick bodies were immunolabeled by the anti-3-repeat tau antibody. The anti-4-repeat tau antibody recognized abnormal tubules comprising neurofibrillary tangles, coiled bodies and argyrophilic threads in progressive supranuclear palsy (PSP) and corticobasal degeneration. In the pre-embedding immunoelectron microscopic study using the phosphorylated tau AT8 antibody, tuft-shaped astrocytes of PSP were found to be composed of bundles of abnormal tubules in processes and perikarya of protoplasmic astrocytes. In this study, the 3-repeat tau or 4-repeat tau epitope was detected in situ at the ultrastructural level in abnormal tubules in representative pathological lesions in Pick's disease, PSP and corticobasal degeneration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17080728     DOI: 10.1111/j.1440-1789.2006.00669.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  38 in total

1.  A Novel Tau Mutation in Exon 12, p.Q336H, Causes Hereditary Pick Disease.

Authors:  Pawel Tacik; Michael DeTure; Kelly M Hinkle; Wen-Lang Lin; Monica Sanchez-Contreras; Yari Carlomagno; Otto Pedraza; Rosa Rademakers; Owen A Ross; Zbigniew K Wszolek; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2015-11       Impact factor: 3.685

Review 2.  Protein astrogliopathies in human neurodegenerative diseases and aging.

Authors:  Gabor G Kovacs; Virginia M Lee; John Q Trojanowski
Journal:  Brain Pathol       Date:  2017-09       Impact factor: 6.508

3.  Is it Useful to Classify Progressive Supranuclear Palsy and Corticobasal Degeneration as Different Disorders? No.

Authors:  Günter U Höglinger
Journal:  Mov Disord Clin Pract       Date:  2018-03-06

4.  Tau protein assembles into isoform- and disulfide-dependent polymorphic fibrils with distinct structural properties.

Authors:  Yoshiaki Furukawa; Kumi Kaneko; Nobuyuki Nukina
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

5.  Anti-MAG autoantibodies are increased in Parkinson's disease but not in atypical parkinsonism.

Authors:  Ewa Papuć; Konrad Rejdak
Journal:  J Neural Transm (Vienna)       Date:  2016-10-20       Impact factor: 3.575

Review 6.  N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.

Authors:  David Olivares; Varun K Deshpande; Ying Shi; Debomoy K Lahiri; Nigel H Greig; Jack T Rogers; Xudong Huang
Journal:  Curr Alzheimer Res       Date:  2012-07       Impact factor: 3.498

7.  Asparagine residue 368 is involved in Alzheimer's disease tau strain-specific aggregation.

Authors:  Shotaro Shimonaka; Shin-Ei Matsumoto; Montasir Elahi; Koichi Ishiguro; Masato Hasegawa; Nobutaka Hattori; Yumiko Motoi
Journal:  J Biol Chem       Date:  2020-08-05       Impact factor: 5.157

Review 8.  Tau-based treatment strategies in neurodegenerative diseases.

Authors:  Anja Schneider; Eckhard Mandelkow
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

9.  Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.

Authors:  Garrett S Gibbons; Rachel A Banks; Bumjin Kim; Lakshmi Changolkar; Dawn M Riddle; Susan N Leight; David J Irwin; John Q Trojanowski; Virginia M Y Lee
Journal:  J Neuropathol Exp Neurol       Date:  2018-03-01       Impact factor: 3.685

Review 10.  Is tau ready for admission to the prion club?

Authors:  Garth F Hall; Brian A Patuto
Journal:  Prion       Date:  2012-07-01       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.